DIRS.INFO The most relevant business & tech news

Such forecasts have prompted a sell-off in a wide range of companies from makers of bariatric surgery devices to companies whose products address the health issues created by excess weight, from diabetes to sleep apnea. "The market is in a shoot-first, ask-questions-later mood when it comes to weight-loss drugs," said Nicholas Anderson, manager of the Thornburg International Growth Fund, which holds shares of Novo Nordisk. By contrast, the iShares U.S. Medical Devices exchange-traded fund has lost more than 22% in the last three months. Injectable weight-loss drugs, known as GLP-1 receptor agonists, are considered highly effective but are also expensive, costing more than $1,300 per month. "Overall, we'll see an increased interest in bariatric surgery, but that will get delayed in the short term."

Persons: Doctor Thomas Horbach, Wegovy, Nicholas Anderson, Eli Lilly, Kenneth Stein, Margaret Kaczor Andrew, William Blair, Michael Farrell, Jeff Jonas, Johnson, Myriam Curet, Ann Hynes, Hynes, David Gaffen, Manas, Michael Erman, Caroline Humer, Sonali Paul Organizations: Novo Nordisk, Healthcare, Growth Fund, Medical Devices, Boston, Gabelli Funds, Johnson, Reuters, Mizuho Securities, Manas Mishra, Thomson Locations: Germany, Munich, Danish, U.S, Boston, GLP, New York, Bengaluru

☆ Ad spending for obesity, diabetes drugs is soaring this year, as drugmakers shell out nearly $500 million
▼ + stars: | 2023-09-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +1 min

Drugmakers spent nearly $500 million on advertisements for obesity and diabetes treatments in the U.S. during the first seven months of this year, up 20% from the same period a year ago, according to new data released Friday. The data, from advertising analytics firm MediaRadar, demonstrates the rush by companies to capture new customers after months of hype around Novo Nordisk 's diabetes drug Ozempic and weight loss counterpart Wegovy. Those drugs and similar treatments have soared in demand this year for their ability to help patients lose unwanted pounds. U.S. health-care providers wrote more than 9 million prescriptions for Ozempic, Wegovy, and other obesity and diabetes drugs during the last three months of 2022, up 300% from early 2020. The top four drugs advertised were Novo Nordisk's Ozempic, Wegovy and diabetes pill Rybelsus and Boehringer Ingelheim's own diabetes treatment Jardiance, which is set to face drug price negotiations with the federal Medicare program.

Persons: Doctor Thomas Horbach, Wegovy, Drugmakers, MediaRadar, Boehringer Organizations: Novo Nordisk, Novo Nordisk's Ozempic Locations: Germany, Munich, U.S

A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo Acquire Licensing RightsFRANKFURT, Aug 24 (Reuters) - Supplies of Novo Nordisk's (NOVOb.CO) popular weight-loss drug Wegovy are limited in Germany less than a month after its launch in Europe's largest drug market, major drug distributors and doctors told Reuters. The volumes of the weekly injection that the Danish drugmaker has delivered to the country so far have fallen short of strong demand, the wholesalers said. "Demand is by far exceeding the available volumes," a spokesperson for Noweda, which has almost a quarter of the German drug wholesale trade, told Reuters, adding the problem was nationwide. The distributors, which act as go-betweens for drug companies and pharmacies, declined to give details of volumes.

Persons: Jim Vondruska, Thomas Horbach, Sanacorp, Pharmahandel, Pharma Privat, Helios St, Elisabeth Klinik, Jodok Fink, ”, Ludwig Burger, Maggie Fick, Josephine Mason, Mark Potter Organizations: REUTERS, Rights, Reuters, Noweda, Novo, Pharma, Thomson Locations: Chicago , Illinois, U.S, Novo, Germany, Europe, Munich, Oberhausen, Freiburg, Frankfurt, London

Interviews with seven doctors and two other potential users of Wegovy from Germany, where Novo Nordisk's (NOVOb.CO) weight-loss drug will become available at the end of July, show the office administrator isn't alone. Allianz (ALVG.DE) says it will pay if a physician diagnoses a medical need while Debeka said its plans exclude weight-loss treatments. In Germany, Wegovy will be administered with the same injection pen used in Norway and Denmark, not the one used in the United States to avoid hitting supplies there. "Patients are so desperate in Germany that they will pay out of their pocket for the medication." "My experience is that people will be able to pay for it out of (their own) pocket," said Horbach.

Persons: Doctor Thomas Horbach, Wegovy, Novo, Jessica Lenth, isn't, I've, Lenth, Debeka, Robert Koch, Danish drugmaker, Sylvia Weiner, Karl Rheinwalt, Thomas Horbach, Weiner, Rheinwalt, Juergen Ordemann, Michael Wirtz, Wirtz, Irina Ernstberger, Ernstberger, Ludwig Burger, Maggie Fick, Patricia Weiss, Josephine Mason, Catherine Evans Organizations: Novo Nordisk, FRANKFURT, Reuters, Allianz, European Union, Robert Koch Institute, Sana Klinikum, St, Hospital, Ozempic, Novo, Thomson Locations: Germany, Munich, LONDON, Hamburg, Wegovy, United States, Danish, Norway, Denmark, Sana, Frankfurt, St Franziskus, Hospital Cologne, Berlin's, Winsen, Lower Saxony, London

Search resuls for: "Thomas Horbach"

4 mentions found